Papanicolaou screening is feasible anywhere that screening for cervical cancer, the leading cause of cancer-related death among women in developing countries, is appropriate. After documenting that the Vietnam War had contributed to the problem of cervical cancer in Vietnam, we participated in a grassroots effort to establish a nationwide cervical cancer prevention program in that country and performed root cause analyses of program deficiencies.
Systems Analysis of Real-World Obstacles to Successful Cervical Cancer Prevention in Developing Countries
Huynh, MD, and Stephen S. Raab, MD Papanicolaou screening is feasible anywhere that screening for cervical cancer, the leading cause of cancer-related death among women in developing countries, is appropriate. After documenting that the Vietnam War had contributed to the problem of cervical cancer in Vietnam, we participated in a grassroots effort to establish a nationwide cervical cancer prevention program in that country and performed root cause analyses of program deficiencies.
We found that real-world obstacles to successful cervical cancer prevention in developing countries involve people far more than technology and that such obstacles can be appropriately managed through a systems approach focused on programmatic quality rather than through ideological commitments to technology. A focus on quality satisfies public health goals, whereas a focus on technology is compatible with market forces. MOST OF THE WORLD'S premature deaths can be prevented with simple, available interventions; what is not clear is how to make these interventions more widely available to the people who need them. 2 Cervical cancer, for example, is both preventable and curable, yet it remains the leading cause of cancer-related death among women in developing countries. 3 Moreover, the impact of this disease is likely to increase over time. Declining birth rates throughout the developing world have induced a profound demographic transition that is leading to a shift in disease burden away from diseases of childhood toward cancer and other diseases of adulthood. 4 Human papillomavirus (HPV; the sexually acquired causative agent of cervical cancer) prophylactic vaccines, prospects for which remain uncertain, may potentially benefit only those generations of women who will not yet have initiated sexual activity by the time putative vaccines are first licensed, and 20 to 30 years may elapse from the time any vaccine is first licensed to the time most people in developing countries have access to it. 5 Any future vaccinated populations will require less screening rather than no screening. 6, 7 When fully successful, conventional Papanicolaou (Pap) cytologic screening reduces cervical cancer rates by 60% to 90% within 3 years of introduction to populations that have not previously been screened; these reductions in incidence and mortality are consistent and dramatic across populations. 8 We have advocated making Pap screening services available without further delay to women in high-risk demographic groups anywhere such services are feasible but unavailable, 9 not because the Pap test will forever remain the most effective cervical screening option in all settings but because, in the case of any setting, it is both prudent and strategically necessary to implement Pap screening before rather than after completing research on either vaccines or what may become an endless series of novel screening technologies. 10 Opportunity costs, borne by the underserved, are associated with prioritizing research on novel health interventions in settings where established interventions are feasible but unavailable, and research on novel screening technologies in developing countries has been justified by understandable yet incorrect assumptions that Pap screening is not feasible in such settings. 11, 12 Groups performing research on novel screening technologies have overestimated costs for Pap tests in developing countries 10-to 100-fold, 9 overlooking the finding that Pap screening programs have been operational in several developing countries for more than 30 years.
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The Pap test is one of the most inexpensive tests in American medicine, and we have suggested setting aside the paradoxical yet commercially useful belief that such a labor-intensive item will be inexpensive in settings where salaries are high but expensive in settings where salaries are low. 9 Assuming that it is not appropriate to screen for cancer in communities without access to curative treatment services, Pap screening appears to be feasible anywhere that cervical screening is appropriate, 9, 14 in that it is difficult to envision either urban or rural communities with access to surgical and radiation therapy services but not to cytology laboratories. Past failures of cervical screening efforts in developing countries can be directly related not to technological limitations of the screening test but to failures in system quality management,  OPPORTUNITIES AND DEMANDS IN PUBLIC HEALTH SYSTEMS  from technology toward quality is therefore essential. 9 Sociopolitical obstacles to achievement of adequate programmatic quality are widespread and may arise when improved quality, which increases the likelihood of beneficial outcomes among recipients of care, does not increase the likelihood of increased incomes among providers of care. 18 We have suggested that interactions between programmatic quality and related sociopolitical obstacles will be elucidated by following the money as well as the science involved with cervical screening activities. 18 Here we propose that real-world obstacles to successful cervical cancer prevention in developing countries are more appropriately addressed through a systems approach incorporating root cause analysis and focused on the concept of health care quality than through an ideological commitment to a single programmatic component.
We also suggest that a focus on quality is more compatible with public health and humanitarian goals, whereas a focus on technology is more readily aligned with market forces.
METHODS
War is associated with male sexual promiscuity, which in turn contributes to the development of cervical cancer among sexually monogamous women.
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In 1996, a case-control study sponsored by Stanford University documented that the Vietnam War had contributed substantially to the problem of cervical cancer in contemporary Vietnam, 19 with screening for public health departments may delay development of budgets; higher vaccine unit costs screening programs pending vaccine may lower coverage rates of both development vaccination and screening programs Note. HPV = human papillomavirus. a Measurement of screening and treatment activity limited to nonverifiable, self-reported activity logs.
reviews. Because certain research and commercial interests represent obstacles to success in Vietnam, 31 we also conducted interviews with research personnel and industry representatives attending international health conferences and obtained further information through literature reviews. On the basis of our root cause analyses, we constructed a system map outlining obstacles to successful cervical screening to display how changes in each area of the system of cervical cancer prevention activities affect other areas.
RESULTS
The results assembled from our interviews and literature reviews were categorized according to the perspectives of different groups of program participants and are presented in Table 1 . This system map outlines some of the ways in which competing incentives among groups with shared interests in cervical cancer prevention affect program success, defined as ensuring that 100% of women in high-risk target demographic groups are screened and receive appropriate follow-up and treatment.
 OPPORTUNITIES AND DEMANDS IN PUBLIC HEALTH SYSTEMS 

Screening Test Collectors' Perspective
The results from our literature review show the well-recognized obstacle to successful cervical cancer prevention in developing countries 35 like Vietnam: an overreliance on reproductive health services for Pap test collection. Unfortunately, the target age group for reproductive health services and the target age group for cervical screening services barely overlap. As a result of the transition toward a market economy in Vietnam, increases in private-sector health provider incomes have dramatically outpaced increases in public-sector incomes, producing incentives against conducting Pap screening in the public sector.
Pathology Laboratory Personnel Perspective
Root causes of suboptimal diagnostic performance in Vietnamese laboratories were similar to those previously reported for American and Mexican laboratories [36] [37] [38] and included obsolete supplies, poorly maintained microscopes, insufficient training, and suboptimal working conditions. The results from our interview with pathologists in developing countries show that cytotechnologists are often allocated insufficient time to perform microscopic examinations of Pap tests, which adversely impacts detection rates of cervical neoplasia.
Dysplasia Treatment Personnel Perspective
We found that salary differentials between the private and public sectors were far more pronounced for physicians than for other health providers, yielding few financial incentives to follow-up on women with In the case of visual screen and treat, screen-positive women undergo cryosurgery before the possibility of invasive carcinoma has been excluded, which has problematic implications for provider acceptance, patient safety, and informed consent. 10 Approximately 18% to 71% of women screened will be informed that they have a positive cervical cancer screening test, that cryosurgery will probably render it impossible for anyone to determine whether cancer is present, and, if cancer is in fact present, that cryosurgery will be ineffective.
Public Health Departments' Perspective
There appears to be a genuine lack of support for cervical cancer prevention efforts within the political structures of many developing countries, 49 
Manufacturers' Perspective
All for-profit corporations have fiduciary obligations to shareholders who are interested primarily in return on investment. Certain business strategies intended to benefit shareholders have been appropriately criticized by public health authorities. 53 
DISCUSSION
As cervical cancer, a preventable public health problem, escalates with mathematical certainty throughout the developing world, our analysis shows that developing country health systems are struggling to succeed against an array of real-world obstacles, including nongovernmental organizations and academic investigators distracted by fund-raising obligations disconnected from public health goals (Table 1) Disease prevention requires social change, which in turn requires the participation of those for whom the change is intended, 85 including demographic groups at high risk for disease, appropriate governmental authorities, and essential medical personnel. 21 Both locally and globally, sociopolitical problems associated with sustaining working coalitions from groups with shared interests but competing incentives constitute critically important real-world obstacles to successful cervical cancer prevention and will remain so irrespective of the screening method(s) eventually used. 21 In settings where health systems cannot afford to ignore such incentives, laboratory data constitute an essential yet sometimes overlooked fulcrum against which to leverage the social change required to preserve life. 6, 10 In addition, many proponents of visual inspection for routine service also recommend taking a biopsy before the ablative treatment (wherever pathology services exist). 10 The drawbacks of cytology are now well understood in resource-poor settings. VIA offers a viable alternative that deserves consideration on the basis of the evidence.
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"Feasibility" refers to that which is possible, in addition to that which is operational, successful, or sustained. Papanicolaou screening is feasible anywhere cervical screening is appropriate, because it is not appropriate to screen for cancer among communities without access to curative treatment services, and because communities with access to curative treatment will also have access to cytology laboratories. Papanicolaou screening is the only preventive option currently available for public sector control of cervical cancer in developing countries. 1 Because future screening programs based on alternative screening tests will require cytology as an essential triage component, visual inspection with acetic acid (VIA), human papillomavirus, and cytology tests may be appropriately regarded as complementary rather than competitive. 2 Research on alternative screening tests in developing countries has unfortunately been justified by incorrect assumptions that Papanicolaou screening is not feasible in lowresource settings where screening is appropriate. Because these incorrect assumptions undermine progressive public health leaders and empower apologists for the status quo, nongovernmental organizations and investigators distracted by fundraising obligations disconnected from public health goals engender significant obstacles to successful cervical cancer prevention in developing countries. Tsu does not specify why management procedures used for follow-up in research settings cannot be used in real-world settings.
We regret any confusion caused by the inference that "abnormal" rates of 20% to 39%, added to "atypical" rates of 37% to 49%, 3 suggest a test-positive rate of 71% for VIA. VIA remains a feasible screening test for premenopausal but not postmenopausal women. 1 Because individuals with positive screening tests understandably desire to know whether they truly have cancer, the implementation of VIA in real-world settings will require confirmatory testing, such as the biopsies suggested by Tsu, that will in turn require cytologic triage. Screening strategies-including VIA "screen and treat"-that do not provide required confirmatory testing should be considered obsolete. Foege et al. 4 have observed that a lack of management skills appears to be the single most important obstacle to improving health throughout the world. 4 That research on novel technologies in developing countries may be more compatible with market forces than with public health goals adds additional complexity to the situation. It would be paradoxical to suggest that Program for Appropriate Technology in Health (PATH) is partnered with yet uninfluenced by human papillomavirus (HPV) test manufacturers. For example, PATH's partnership with Digene Corporation (Gaithersburg, MD) presents a source of potential bias in favor of HPV screening that should be disclosed to readers of Alliance for Cervical Cancer Prevention cost-effectiveness studies. 6 Because dozens of public-private partnerships have recently been established with philanthropic funding in global health, 5 PATH should set a leading example by fully disclosing the terms of its public-private partnerships, including any arrangements for revenue sharing from future sales of HPV tests. More than 7 years after the founding of the Alliance for Cervical Cancer Prevention, cytology remains the only preventive option available for public-sector cervical cancer control in developing countries. 7 HPV vaccination, the long-term effectiveness of which remains uncertain, is currently unaffordable, as is HPV screening. Quality management methods are not established for visual inspection with acetic acid, which is not recommended for use outside of pilot projects and is inappropriate for postmenopausal women in any setting. 7 Because cytology will be an essential triage component of future "screen and treat" or multiple-visit HPV-based or visual inspection with acetic acid programs, 1,2,4 we entreat Sherris et al. to endorse, on the Web site for Alliance for Cervical Cancer Prevention, a patient-centered consensus policy whereby Pap screening will be implemented anywhere cervical screening is appropriate but unavailable, with consideration given to novel preventives as locality-specific research into novel preventives is completed. 2, 4 Proponents of the alternative policy-to further delay the implementation of Pap screening in some settings pending the unlikely realization of cytology-free preventive approaches with decisive advantages over approaches incorporating some cytology-are unfortunately enamored with the promise of novel approaches at the expense of delivering available preventives today.
